These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38989283)

  • 1. Case report: Disitamab vedotin combined with immunotherapy demonstrated excellent efficacy in scrotal Paget's disease with Her-2 overexpression.
    Wang JL; Meng WJ; Hu N; Liu JY
    Front Immunol; 2024; 15():1349033. PubMed ID: 38989283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful human epidermal growth receptor 2-targeted therapy beyond disease progression for extramammary Paget's disease.
    Watanabe S; Takeda M; Takahama T; Iwasa T; Tsurutani J; Tanizaki J; Shimizu T; Sakai K; Wada Y; Isogai N; Nishio K; Nakagawa K
    Invest New Drugs; 2016 Jun; 34(3):394-6. PubMed ID: 26856856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modified weekly regimen of cisplatin, epirubicin and paclitaxel induced a durable response in two cases of metastatic extramammary Paget's disease.
    Hirai I; Funakoshi T
    J Dermatol; 2017 Oct; 44(10):1148-1151. PubMed ID: 28406527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The expression of HER-2 in extramammary Paget's disease.
    Masuguchi S; Jinnin M; Fukushima S; Makino T; Sakai K; Inoue Y; Igata T; Ihn H
    Biosci Trends; 2011 Aug; 5(4):151-5. PubMed ID: 21914949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of HER2 status in extramammary Paget disease and its implication for disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate therapy.
    Jia J; Mao L; Lin J; Li W; Yuan P; Guo L; Dai J; Li C; Bai X; Li Z; Chen Y; Guo J; Ying J; Si L
    Front Med; 2024 Jun; 18(3):565-569. PubMed ID: 38743132
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinicopathologic characteristics of extramammary Paget's disease of the scrotum associated with sweat gland adenocarcinoma-a clinical retrospective study.
    Yan D; Dai H; Jin M; Zhao Y
    J Chin Med Assoc; 2011 Apr; 74(4):179-82. PubMed ID: 21463849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the biomarkers for targeted therapies in primary extra-mammary and mammary Paget's disease.
    Gatalica Z; Vranic S; Krušlin B; Poorman K; Stafford P; Kacerovska D; Senarathne W; Florento E; Contreras E; Leary A; Choi A; In GK
    Cancer Med; 2020 Feb; 9(4):1441-1450. PubMed ID: 31899853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose-rate brachytherapy in scrotal extramammary Paget's disease: A case report.
    Risso S; Amendola BE; Perez NC; Amendola M
    Brachytherapy; 2023; 22(2):210-213. PubMed ID: 36509648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Disitamab Vedotin in a heavily pre-treated HER2 positive lung adenocarcinoma patient: case report and literature review.
    Qi X; Guo J; Zhou X; Sun L; Lin J; Huang Z; Chen H; Lin L
    Heliyon; 2022 Sep; 8(9):e10581. PubMed ID: 36185140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety analysis of a HER2-targeting antibody-drug conjugate combined with immune checkpoint inhibitors in solid tumors: a real-world study.
    Zhou YX; Wang JL; Mu XL; Zhu YJ; Chen Y; Liu JY
    Aging (Albany NY); 2023 Dec; 15(24):15473-15488. PubMed ID: 38147019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment outcomes of advanced/metastatic extramammary Paget's disease in Korean patients: KCSG-RC20-06.
    Sohn BS; Kim J; Kim M; Hong JY; Lee J; Park SE; Kim H; Lee HJ; Kang EJ; Lee SI; Lee IH; Huh SJ; Jo J; Kim HY
    Cancer Med; 2023 Jul; 12(14):15159-15175. PubMed ID: 37264748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor Wide Horizontal Invasion Predicts Local Recurrence for Scrotal Extramammary Paget's Disease.
    Wang L; Feng C; Zhou M; Zhou Z; Ding G; Gao P; Ding Q; Wu Z
    Sci Rep; 2017 Mar; 7():44933. PubMed ID: 28322288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human epidermal growth factor receptor-2 (HER2) is a potential therapeutic target in extramammary Paget's disease of the vulva.
    Bartoletti M; Mazzeo R; De Scordilli M; Del Fabro A; Vitale MG; Bortot L; Nicoloso MS; Corsetti S; Bonotto M; Scalone S; Giorda G; Sorio R; Andreetta C; Meacci ML; De Vivo R; Fasola G; Sopracordevole F; Puglisi F
    Int J Gynecol Cancer; 2020 Nov; 30(11):1672-1677. PubMed ID: 32998859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment with imiquimod and surgical excision of a patient with extramammary Paget's disease. Case report].
    Olazarán-Medrano Z; Treviño-González JJ; Salas-Alanís JC; Lemus-Arias JA
    Rev Med Inst Mex Seguro Soc; 2010; 48(1):83-6. PubMed ID: 20696113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic extramammary Paget's disease treated with paclitaxel and trastuzumab combination chemotherapy.
    Takahagi S; Noda H; Kamegashira A; Madokoro N; Hori I; Shindo H; Mihara S; Hide M
    J Dermatol; 2009 Aug; 36(8):457-61. PubMed ID: 19691751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case report: Pyrotinib in the treatment of advanced scrotal EMPD combined with sweat gland carcinoma.
    Zhu L; Wang H; Cheng D; Wang W; Lei Y; Yang N; Peng L; Liu P; Zhou J; Xie B
    Front Oncol; 2024; 14():1382376. PubMed ID: 39045556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extramammary Paget's Disease in Two Brothers.
    Zhang X; Jin W; Zhu H; Yu H
    Indian J Dermatol; 2015; 60(4):423. PubMed ID: 26288451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disitamab Vedotin: First Approval.
    Deeks ED
    Drugs; 2021 Nov; 81(16):1929-1935. PubMed ID: 34661865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of mohs microgrpahic resection for cutaneous malignancy involving the scrotum.
    Roberson D; Chelluri R; Skokan AJ; Xia L; Heavner MG; Lukowiak T; Schwartz L; Lee DJ; Guzzo TJ; Kovach SJ; Miller C; Kovell RC
    Urol Oncol; 2021 Aug; 39(8):501.e11-501.e16. PubMed ID: 34187750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of low-dose 5-fluorouracil/cisplatin therapy for invasive extramammary Paget's disease.
    Kato H; Watanabe S; Kariya K; Nakamura M; Morita A
    J Dermatol; 2018 May; 45(5):560-563. PubMed ID: 29446148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.